ecancer

HER2-low mBC patients report preserved QOL with trastuzumab deruxtecan

Prof Naoto Ueno - The University of Texas MD Anderson Cancer Center, Houston, USA

11 Sep 2022

Lasofoxifene shows promise for women with ESR1-mutated mBC

Prof Hope Rugo - UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, USA

11 Sep 2022

Extended adjuvant AI not advised for HPBC after 5+ yrs of sequential endocrine therapy

Dr Vivianne Tjan-Heijnen - Maastricht University Medical Center, Maastricht, Netherlands

11 Sep 2022

Prognostic model of all-cause mortality at 30 days in patients with cancer and COVID-19

Dr Chris Labaki - Dana-Farber Cancer Institute, Boston, USA

11 Sep 2022

Metastatic breast cancer endpoints for survival: rwPFS and TTNT

Dr Chris Labaki - Dana-Farber Cancer Institute, Boston, USA

10 Sep 2022

New data presented at ESMO for multi-cancer early detection

Dr Tom Beer - Vice President and Chief Medical Officer of Exact Sciences

10 Sep 2022

Olaparib continues to show positive results in advanced ovarian cancer - 7 year data

Prof Paul DiSilvestro - Women & Infants Hospital, Providence, USA

10 Sep 2022

OncoAlert and ecancer weekly round up for August 15th - 21st, 2022

Dr Gil Morgan - Skåne University Hospital in Lund, Sweden

22 Aug 2022

Working to improve global cancer care access in low middle-income countries

Dr Julie Gralow, Prof Eduardo Cazap

25 Jul 2022

Palbociclib shows improved PFS but not improved OS for ER+ HER2- mBC patients

Dr Bishal Gyawali - Queen's University, Kingston, Canada

19 Jul 2022

Breast cancer and survivorship

Dr. Ashwin Mehta - Memorial Healthcare System, Florida, USA

8 Jul 2022

Latest updates in hormone receptor positive HER2 negative breast cancer

Dr Mariana Chavez MacGregor - MD Anderson Cancer Center, Houston, USA

8 Jul 2022

More from ecancer